82P Preliminary analysis of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC). (December 2022) - Wang, T.; L. Li,; Huang, L.; Liu, J.; Zhu, D.D.; Qin, C.; Dong, J.; Deng, H.; Zheng, X.; Tian, L.; Jiang, L.; Wang, W.; et al.